These reports were presented at EASL in Vienna Spring 2006:
VX-950 HCV Protease Inhibitor Resistance Profile - (05/02/06)
Initial Results of a 14-Day Study of the Hepatitis C Virus Protease Inhibitor VX-950, In Combination with Peginterferon-alfa-2a - (05/02/06)
Subsequent to EASL at DDW, the 28-day study in which VX-950 was stopped but patients continued with Pegasys+RBV was reported:
VX-950 HCV Protease Inhibitor + Pegasys/RBV: 28 days study results in treatment-naive - (05/24/06)
NATAP nataphcv mailing list -- nataphcv@...
[Non-text portions of this message have been removed]